Non-small cell lung cancer (NSCLC) is not a single disease. It is a group of biologically distinct subtypes that differ in histology, molecular profile, and treatment response. For researchers working in this space, understanding that diversity is not just helpful, it is essential. The different types of non-small cell lung cancer call for different models, markers, and experimental approaches, especially when studying mechanisms like resistance, immune evasion, or drug response. But what are the major NSCLC subtypes, and how does their unique biology shape the tools and strategies researchers use to study them?

The types of non-small cell lung cancer

NSCLC comprises roughly 80-85% of lung cancers¹, split into three main histological categories:

• Adenocarcinoma: The most prevalent subtype, often found in non-smokers and peripheral lung regions. These tumors usually express TTF-1 and Napsin A and may harbor targetable mutations like EGFR or ALK rearrangements².
• Squamous cell carcinoma: Strongly associated with smoking and typically located more centrally. These tumors show keratinization and intercellular bridges and are marked by p40, CK5/6, and p63 expression.
• Large cell carcinoma: Less common and diagnosed by exclusion when no glandular or squamous differentiation is visible. Often reclassified when better markers are used.

These histological categories are the foundation for how we define, compare, and study NSCLC in the lab.

Why mutation still matters at the bench

Once the histological subtype of NSCLC has been defined, molecular profiling adds another layer of context. Even if designing targeted therapies is not the goal, knowing which mutations are present in a system helps researchers select the right tools, accurately interpret data, and assess how closely a model reflects patient biology.

Here is a snapshot of key molecular drivers:

• EGFR mutations: Sensitize tumors to tyrosine kinase inhibitors (TKIs) like osimertinib³.
• ALK or ROS1 rearrangements: Found in younger, non-smokers. Responsive to ALK/ROS1 inhibitors⁴.
• KRAS mutations: Common but historically undruggable until recently, with G12C-specific inhibitors like sotorasib⁵.
• MET exon 14 skipping and BRAF V600E mutations: Smaller subsets, but both targetable with FDA-approved therapies⁶.
• PD-L1 expression: A key predictor of immunotherapy response, particularly for checkpoint inhibitors like pembrolizumab⁷.

Even if you are not studying these mutations directly, understanding which ones are present helps you plan, validate, and troubleshoot your experiments more effectively.

Choosing the right model

Whether you are working with a cell line, a mouse model, or patient-derived material, understanding how each system reflects your NSCLC subtype helps you plan your experiments with more clarity. Although no model captures the full complexity of the types of non-small cell lung cancer, each has its strengths. Knowing what those are can help you choose the right assays, interpret your results, and set expectations around translatability.

Here is how some common NSCLC model types compare:

Understanding the strengths and weaknesses of whichever system you use can help you design more focused experiments and interpret your data confidently. The goal is not to find a perfect model, but to know how your model relates to the biology you’re studying.

Biomarkers that support experimental design

Even when you're working with a well-characterized model, it's not always clear what you should measure, or how to confirm your system is doing what you expect. This table highlights common NSCLC biomarkers and how they can support experimental decisions, from validating model identity to interpreting drug responses:

Whether you're running an IHC panel, planning a flow assay, or troubleshooting unexpected data, these markers give you a clearer picture of your system's state.

Get specific to stay confident in your results

When you are working with a complex disease like NSCLC, knowing the mutation or subtype isn’t enough on its own. You need to understand how that biology plays out in your model. Minor mismatches can lead to confusing data or misinterpreted results.

The types of non-small cell lung cancer are not just clinical classifications, they are experimental variables. Markers, models, and mechanisms are all connected. The more specific you are upfront, the more confident you can be in what your data is telling you. Therefore, whether you are studying resistance pathways, tumour–immune interactions, or new therapeutic targets, it is worth ensuring your system fully aligns with your question. It is not overkill. It is just good science.

1. References

2. Types of lung cancer. https://www.cancerresearchuk.org/about-cancer/lung-cancer/stages-types/types (accessed 2025-07-30).
3. Rotow, J.; Bivona, T. G. Understanding and Targeting Resistance Mechanisms in NSCLC.Nat. Rev. Cancer2017,17 (11), 637–658. https://doi.org/10.1038/nrc.2017.84.
4. Gahr, S.; Stoehr, R.; Geissinger, E.; Ficker, J. H.; Brueckl, W. M.; Gschwendtner, A.; Gattenloehner, S.; Fuchs, F. S.; Schulz, C.; Rieker, R. J.; Hartmann, A.; Ruemmele, P.; Dietmaier, W. EGFR Mutational Status in a Large Series of Caucasian European NSCLC Patients: Data from Daily Practice.Br. J. Cancer2013,109 (7), 1821–1828. https://doi.org/10.1038/bjc.2013.511.
5. Remon, J.; Pignataro, D.; Novello, S.; Passiglia, F. Current Treatment and Future Challenges in ROS1- and ALK-Rearranged Advanced Non-Small Cell Lung Cancer.Cancer Treat. Rev.2021,95. https://doi.org/10.1016/j.ctrv.2021.102178.
6. Lim, T. K. H.; Skoulidis, F.; Kerr, K. M.; Ahn, M. J.; Kapp, J. R.; Soares, F. A.; Yatabe, Y. KRAS G12C in Advanced NSCLC: Prevalence, Co-Mutations, and Testing.Lung Cancer2023,184 (107293). https://doi.org/10.1016/j.lungcan.2023.107293.
7. Reale, M. L.; Passiglia, F.; Cappuzzo, F.; Minuti, G.; Occhipinti, M.; Bulotta, A.; Delmonte, A.; Sini, C.; Galetta, D.; Roca, E.; Pelizzari, G.; Cortinovis, D.; Gariazzo, E.; Pilotto, S.; Citarella, F.; Bria, E.; Muscolino, P.; Pozzessere, D.; Carta, A.; Pignataro, D.; Calvetti, L.; Leone, F.; Banini, M.; Di Micco, C.; Baldini, E.; Favaretto, A.; Malapelle, U.; Novello, S.; Pasello, G.; Tiseo, M. MET Exon 14 Skipping Mutations in Non-Small-Cell Lung Cancer: Real-World Data from the Italian Biomarker ATLAS Database.ESMO Open2024,9 (9), 103680. https://doi.org/10.1016/j.esmoop.2024.103680.
8. Cortellini, A.; Brunetti, L.; Fazio, G. R. D.; Garbo, E.; Pinato, D. J.; Naidoo, J.; Katz, A.; Loza, M.; Neal, J. W.; Genova, C.; Gettinger, S.; Kim, S. Y.; Jayakrishnan, R.; Zarif, T. E.; Russano, M.; Pecci, F.; Federico, A. D.; Awad, M.; Alessi, J. V.; Montrone, M.; Owen, D. H.; Signorelli, D.; Fidler, M. J.; Li, M.; Camerini, A.; Giglio, A. D.; Young, L.; Vincenzi, B.; Metro, G.; Passiglia, F.; Yendamuri, S.; Guida, A.; Ghidini, M.; Awosika, N. O.; Napolitano, A.; Fulgenzi, C. A. M.; Grisanti, S.; Grossi, F.; D’Incecco, A.; Josephides, E.; Hemelrijck, M. V.; Russo, A.; Gelibter, A.; Spinelli, G.; Verrico, M.; Tomasik, B.; Giusti, R.; Newsom-Davis, T.; Bria, E.; Sebastian, M.; Rost, M.; Forster, M.; Mukherjee, U.; Landi, L.; Mazzoni, F.; Aujayeb, A.; Dupont, M.; Curioni-Fontecedro, A.; Chiari, R.; Pantano, F.; Morabito, A.; Leonetti, A.; Friedlaender, A.; Addeo, A.; Zoratto, F.; Tursi, M. D.; Cantini, L.; Roca, E.; Mountzios, G.; Gravara, L. D.; Kalvapudi, S.; Inno, A.; Bironzo, P.; Barros, R. D. M.; O’Reilly, D.; Bell, J.; Karapanagiotou, E.; Monnet, I.; Baena, J.; Macerelli, M.; Majem, M.; Agustoni, F.; Cortinovis, D. L.; Tonini, G.; Minuti, G.; Bennati, C.; Mezquita, L.; Gorría, T.; Servetto, A.; Beninato, T.; Russo, G. L.; Rogado, J.; Moliner, L.; Biello, F.; Nana, F. A.; Dingemans, A.-M.; Aerts, J. G. J. V.; Ferrara, R.; Torri, V.; Hejleh, T. A.; Takada, K.; Naqash, A. R.; Garassino, M.; Peters, S.; Wakelee, H.; Nassar, A. H.; Ricciuti, B. Determinants of 5-Year Survival in Patients with Advanced NSCLC with PD-L1≥50% Treated with First-Line Pembrolizumab Outside of Clinical Trials: Results from the Pembro-Real 5Y Global Registry. J. Immunother. Cancer2025,13 (2). https://doi.org/10.1136/jitc-2024-010674.